General
Preferred name
NARATRIPTAN
Synonyms
GR-85548A D3 ()
Naratriptan (D3 Hydrochloride) ()
Naratriptan HCl ()
Amerge ()
Naramig ()
GR-85548A hydrochloride ()
Naratriptan (hydrochloride) ()
NARATRIPTAN HYDROCHLORIDE ()
GR-85548A ()
GR 85548A ()
Naratriptan ()
P&D ID
PD009622
CAS
143388-64-1
121679-13-8
Tags
available
drug
Approved by
FDA
First approval
1998
Drug indication
Migraine
Headache
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Naratriptan (GR-85548A) hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 ¦ÌM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms[1][2][3][4].
PRICE
35
DESCRIPTION
Marketed formulations may contain naratriptan hydrochloride (PubChem CID 60875).
(GtoPdb)
PRICE
79
DESCRIPTION
Naratriptan Hydrochloride is the hydrochloride salt form of naratriptan, a sulfonamide with selective serotonin (5-HT) 1 receptor agonistic activity and anti-migraine property. Naratriptan hydrochloride (GR-85548A hydrochloride) binds selectively and with high affinity to the 5-HT1D and 5-HT1B receptor subtypes. Activation of these 5-HT1D/B receptors located on intracranial blood vessels leads to vasoconstriction and provides relief of migraine headaches. Naratriptan hydrochloride may also exerts its effect by stimulation of 5-HT1D/1B receptors on sensory nerve endings in the trigeminal system thereby decreasing the release of pro-inflammatory neuropeptides.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Naratriptan, a 5-HT1B/1D receptor agonist, could be used in the treatment of migraine.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Naratriptan is a selective agonist of 5-HT1 receptor and is is used for the treatment of migraine headaches.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
29
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
87
Molecular Weight
335.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
2.07
TPSA
65.2
Fraction CSP3
0.53
Chiral centers
0.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT1
HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
Pathway
Neuronal Signaling
GPCR/G protein
Neuroscience
Indication
migraine headache
MOA
serotonin receptor agonist
Therapeutic Class
Vasoconstrictor Agents
Solubility
DMSO 74 mg/mL (198 mM)
Water 22 mg/mL (59 mM)
Source data

